Assessing Treatment for Patients with Pulmonary Arterial Hypertension

Gender Preference	None
Age Group	18 - 75 years
Research Start Date	August 10, 2007
Research End Date	April 30, 2013
Principal Investigator	Sif Hansdottir, MD
Description	AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event. Please refer to www.clinicaltrials.gov identifier NCT01178073 for more information.
Contact Info	Pulmonary Hypertension Program Page Scovel, RN Phone: 319-385-8005 Fax: 319-356-7087 page-scovel@uiowa.edu
Keywords	span itemProp='description'>Heart ; high blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension ;

Contact